ESPR - Esperion's late stage trial of high cholesterol treatment met main goal
2024-05-20 08:33:13 ET
More on Esperion Therapeutics
- Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
- Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript
- Esperion Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Esperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook
- Esperion Therapeutics Q1 2024 Earnings Preview